A bioequivalency profile comparison of extended-release bupropion as produced by Impax Laboratories for Teva and Biovail for GlaxoSmithKline. Note: The generic drug illustrated in this graphic was not affected by the FDA's 300 mg recall and is still available in the United States as of April 2013.[1][2]
to share – to copy, distribute and transmit the work
to remix – to adapt the work
Under the following conditions:
attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
https://creativecommons.org/licenses/by/3.0CC BY 3.0 Creative Commons Attribution 3.0 truetrue